Fibroepithelial tumors of the breast are common benign lesions consisting of epithelial and stromal components. These include fibroadenomas (FAs) and phyllodes tumors (PTs), commonly seen in clinical practice. FAs arise from the epithelium and stroma of the terminal duct lobular unit. The histological hallmark is well-balanced epithelial and stromal proliferation. FAs are the most common benign breast lesions in young females. PTs were first fully characterized in 1838 by Muller [1], and are histologically characterized by epithelial-lined cleft-like spaces with hypercellular stroma, similar to a leaf in architecture. PTs include sub-classifications such as benign, borderline, and malignant, according to the WHO classification [2]. The distinction among the three subgroups is based on the combination of several histologic features. Benign PTs sometimes relapse with higher proliferative activity and may progress to borderline PT or malignant PT. Moreover, benign PTs mimic FAs in histopathology; therefore, both lesions are difficult to distinguish with core needle biopsy (CNB) or vacuum-assisted biopsy (VAB), despite different clinical courses. Almost all patients diagnosed with FA are recommended for follow-up, but surgery may be considered when they exhibit rapid growth or a size greater than 3 cm in imaging. On the other hand, once a patient is diagnosed with a PT by biopsy, regardless the size, wide excision with surgical margins ≥ 1 cm is recommended because of local recurrence [3]. Several studies have tried to find the clinical and histological factors to differentiate PT from FA, but these factors often overlapped. It was reported that the sensitivity of imaging and CNB for diagnosing PTs is 65% and 63% [4], and another report showed that the inter-observer variation was high with CNB when diagnosing fibroepithelial tumors [5]. Moreover, the upstaging to PT from fibroepithelial tumors diagnosed by CNB is often experienced in clinical practice. It was reported that the upstage rate was 37.5% for benign or borderline PTs in excised fibroepithelial tumors [6]. Stromal mitosis might be helpful for differential diagnosis of PT. Finding 2 or more stromal mitoses per 10 HPFs in the CNB specimen may indicate PT [7]. Immunohistochemical studies are also useful for differential diagnosis of fibroepithelial tumors, such as Ki67 or topoisomerase Ⅱ [7]. Nonetheless, a report showed the mitotic counts and these immunostaining findings on CNB materials overlapped between FAs and PTs [8]. Thus, there is no clear definable cut-off of these histological or immunohistochemical features. Tumor heterogeneities result in both the difficulty and the interobserver variation in the diagnosis of fibroepithelial tumors. Therefore, although there are several predictive factors [3, 9–11], distinction between benign PTs and FAs still remains a difficult task, and hence stands as a diagnostic challenge to decide clinical management.
A label-free imaging technique with multi-photon microscopy (MPM), which enables high resolution fluorescence imaging, is attracting much attention as a histopathological diagnostic tool for assessing disease states. This technique has been extensively used for assessment of various diseases, including cancer and fibrosis [12, 13]. The near-infrared beam used for multi-photon excitation can excite endogenous fluorophores which include nicotine amide adenine dinucleotide (NADH), flavin adenine dinucleotide (FAD), elastic fibers, vitamins, and other metabolites [14]. In breast cancer tissues, this autofluorescence (AF) has been used to estimate cellular redox states as well as for assessment of cancers [15, 16]. At the same time, second harmonic generation (SHG) imaging is possible by MPM, which allows direct visualization of molecules possessing non-centrosymmetric molecules such as collagen. SHG imaging played vital roles for evaluating changes in fibrillar organization [17]. Combined SHG and AF imaging was used for diagnosing breast cancers [15, 16, 18–21]. On the other hand, there have been few reported studies which surveyed the relation between benign breast lesions and MPM. Two subtypes of fibroadenomas were investigated using AF and SHG signals [22], and it was reported that measurement of collagen density by SHG imaging is useful for differential diagnosis of breast FAs and PTs [23]. This study simply investigated amounts of the collagen fibrils by quantifying the SHG signals as a potential diagnostic index. Although this achieved over 85% sensitivity and specificity, for more accurate detection, structural information regarding collagenous density and proliferation of lactiferous ducts should be included since fibroepithelial tumors were composed of the proliferation of the stromal and epithelial elements. Therefore, in order to refine signatures that differentiate the lesions more precisely, we took advantage of a machine learning-based approach for quantitative feature detection. Digital pathology is a field of computer-aided detection and evaluation of diseases, aiming to automate assessment. With the advancement of artificial intelligence, this approach is becoming more common in clinical investigations. In this study, we aimed to find novel morphological signatures of the FA and PT fibroepithelial lesions in breast tissues. To investigate whether morphological features which reflect stromal hypertrophy and epithelial proliferation can differentiate the lesions, we performed a pixel-wise semantic segmentation method using a deep learning framework. Accurate separation of epithelial and stromal regions allowed for estimation of the balance of epithelial to stromal regions, which can be a signature for differentiating FAs and PTs. Furthermore, combining this with the collagen SHG signal strength led us to finding a refined index to distinguish FA and PT lesions.